Losartan and Eprosartan Induce a Similar Effect on the Acute Rise in Serum Uric Acid Concentration after an Oral Fructose Load in Patients with Metabolic Syndrome

Anna Masajtis-Zagajewska, Jacek Majer, Michał Nowicki, Anna Masajtis-Zagajewska, Jacek Majer, Michał Nowicki

Abstract

Introduction: Excessive intake of fructose increases serum uric acid concentration. Hyperuricemia induces a negative effect on atherosclerosis and inflammation. Hyperuricemia is common in patients with arterial hypertension. Several antihypertensive drugs including diuretics increase serum uric acid concentration. In contrast, the angiotensin II receptor antagonist (ARB) losartan was found to lower serum uric acid though it may increase renal excretion while other ARBs showed mostly a neutral effect. In this study, effects of two AT1 receptor antagonists losartan and eprosartan on serum uric acid changes induced by oral fructose load were directly compared.

Methods: The randomized, crossover, head-to-head comparative study comprised 16 ambulatory patients (mean age 64.5 ± 9.8 years). The patients fulfilled AHA/NHLBI 2005 criteria of metabolic syndrome. A daily single morning dose of each study drug (50 mg of losartan or 600 mg of eprosartan) was given during two 3-month periods in a random order separated by 2-week washout time. The oral fructose tolerance test (OFTT) was performed at baseline and after each two 3-onth treatment periods. Before and during OFTT, urine excretion of uric acid and creatinine was assessed in the first morning portion of urine. Blood samples for the measurement of serum uric acid and lipids were taken at baseline and 30, 60, and 120 minutes after oral intake of 75 g of fructose.

Results: After 3-month treatment with eprosartan and losartan, both systolic and diastolic blood pressure decreased significantly and to a similar extent. After the treatment, serum uric acid and its baseline and postfructose urine excretion were unchanged. No significant changes of plasma lipids before and after OFTT were observed throughout the study.

Conclusions: The study showed that in patients with hypertension and metabolic syndrome, both losartan and eprosartan have a neutral effect on fasting and postfructose load serum uric acid concentration and its urinary excretion. This trial is registered with NCT04954560.

Conflict of interest statement

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Copyright © 2021 Anna Masajtis-Zagajewska et al.

Figures

Figure 1
Figure 1
Serum uric acid concentration during OFTT (a) and changes of serum uric acid concentration during OFTT (b).
Figure 2
Figure 2
Urine excretion of uric acid during OFTT.

References

    1. Li L., Zhang Y., Zeng C. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. American Journal of Translational Research. 2020;12(7):3167–3181.
    1. Wortmann R. L. Gout and hyperuricemia. Current opinion in rheumatology. 2002;14(3):281–286. doi: 10.1097/00002281-200205000-00015.
    1. Stewart D. J., Langlois V., Noone D. Hyperuricemia and hypertension: links and risks. Integrated blood pressure control. 2019;Volume 12:43–62. doi: 10.2147/IBPC.S184685.
    1. Simon N. M., Jon E., Smucker M. D. Differential uric acid excretion in essential and renal hypertension. Circulation. 1969;39(1):121–125. doi: 10.1161/01.CIR.39.1.121.
    1. Gill D., Cameron A. C., Burgess S., et al. Urate, blood pressure, and cardiovascular disease. Hypertension. 2021;77(2):383–392. doi: 10.1161/HYPERTENSIONAHA.120.16547.
    1. Tykarski A., Posadzy-Małaczyńska A. Mechanism of hyperuricemic action of angiotensin converting enzyme inhibitors in patients with essential hypertension. Journal of Hypertension. 1996;14:219–224.
    1. Burnier M., Hagman M. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension. 1995;25, 4 Part 1:602–609. doi: 10.1161/01.hyp.25.4.602.
    1. Hatch M., Freel R., Vaziri N. Effects of the specific angiotensin II receptor antagonist losartan on urate homeostasis and intestinal urate transport. Journal of Pharmacology and Experimental Therapeutics. 1996;276:187–193.
    1. Tikkanen I., Omvik P., Jensen H. A. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. Journal of Clinical Pharmacology. 1996;36:403–408.
    1. Goldberg A. I., Dunlay M. C., Sweet C. S. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipne ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. The American Journal of Cardiology. 1995;75(12):793–795. doi: 10.1016/S0002-9149(99)80413-5.
    1. Edwards R. M., Trizna W., Stack E., Weinstock J. Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush-border membranes. The Journal of Pharmacology and Experimental Therapeutics. 1996;276(1):125–129.
    1. Portman O. W., Lawry E. Y., Bruno D. Effect of dietary carbohydrate on experimentally induced hypercholesteremia and hyperbetalipoproteinemia in rats. Proceedings of the Society for Experimental Biology and Medicine. 1956;91(2):321–323. doi: 10.3181/00379727-91-22250.
    1. Roch-Ramel F., Diezi J. Renal transport of organic ions and uric acid. In: Schrier R. W., Gottschalk C. W., editors. Diseases of the Kidney. 6. Boston: Little Brown & Co; 1996. pp. 231–249.
    1. Al-Nagdy S., Miller D. S., Yudkin J. Changes in body composition and metabolism induced by sucrose in the rat. Nutrition and Metabolism. 2004;12:193–219.
    1. Sleder J., Chen Y. D., Cully M. D., Reaven G. M. Hyperinsulinemia in fructose-induced hypertriglyceridemia in the rat. Metabolism. 1980;29(4):303–305. doi: 10.1016/0026-0495(80)90001-3.
    1. Bode J. C., Zelder O., Rumpelt H. J., Wittkamp U. Depletion of liver adenosine phosphates and metabolic effects of intravenous infusion of fructose or sorbitol in man and in the rat∗, ∗∗. European Journal of Clinical Investigation. 1973;3(5):436–441. doi: 10.1111/j.1365-2362.1973.tb02211.x.
    1. Nair S., Chacko P. V., Arnold C., Diehl A. M. Hepatic ATP reserve and efficiency of replenishing: comparison between obese and non-obese normal individuals. The American Journal of Gastroenterology. 2003;98(2):466–470. doi: 10.1111/j.1572-0241.2003.07221.x.
    1. Morris R. C., Jr., Nigon K., Reed E. B. Evidence that the severity of depletion of inorganic phosphate determines the severity of the disturbance of adenine nucleotide metabolism in the liver and renal cortex of the fructose-loaded rat. The Journal of Clinical Investigation. 1978;61(1):209–220. doi: 10.1172/JCI108920.
    1. Grundy S. M., Cleeman J. I., Daniels S. R., et al. Diagnosis and management of the metabolic syndrome. Circulation. 2005;112(17):2735–2752. doi: 10.1161/CIRCULATIONAHA.105.169404.
    1. Chen X., Ji Z. L., Chen Y. Z. TTD: therapeutic target database. Nucleic Acids Research. 2002;30(1):412–415. doi: 10.1093/nar/30.1.412.
    1. Bottorff M. B., Tenero D. M. Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations. Pharmacotherapy. 1999;19(4 Part 2):73S–78S. doi: 10.1592/phco.19.7.73s.30946.
    1. Dang A., Zhang Y., Liu G., Chen G., Song W., Wang B. Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population. Journal of Human Hypertension. 2006;20(1):45–50. doi: 10.1038/sj.jhh.1001941.
    1. Puig J. G., Mateos F., Buño A., Ortega R., Rodriguez F., Dal-Ré R. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. Journal of Hypertension. 1999;17(7):1033–1039. doi: 10.1097/00004872-199917070-00021.
    1. Rayner B. L., Trinder Y. A., Baines D., Lionel H. Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics. American Journal of Hypertension. 2006;19(2):208–213. doi: 10.1016/j.amjhyper.2005.08.005.
    1. Elliott W. J., Calhoun D. A., PT D. L., Gazdick L. P., Kerns D. E., Zeldin R. K. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. Clinical Therapeutics. 2001;23(8):1166–1179. doi: 10.1016/S0149-2918(01)80099-0.
    1. Hamada T., Hisatome I., Kinugasa Y., et al. Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects. Internal Medicine. 2002;41(10):793–797. doi: 10.2169/internalmedicine.41.793.
    1. Würzner G., Gerster J. C., Chiolero A., et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. Journal of Hypertension. 2001;19(10):1855–1860. doi: 10.1097/00004872-200110000-00021.
    1. Schmidt A., Gruber U., Böhmig G., Köller E., Mayer G. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. Nephrology, Dialysis, Transplantation. 2001;16(5):1034–1037. doi: 10.1093/ndt/16.5.1034.
    1. Caspi D., Lubart E., Graff E., Habot B., Yaron M., Segal R. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis and Rheumatism. 2000;43(1):103–108. doi: 10.1002/1529-0131(200001)43:1<103::AID-ANR13>;2-C.
    1. Verdecchia P., Staessen J. A., Angeli F., et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet. 2009;374(9689):525–533. doi: 10.1016/S0140-6736(09)61340-4.
    1. Jelic-Ivanovic Z., Spasic S., Majkic-Singh N., Todorovic P. Effects of some anti-inflammatory drugs on 12 blood constituents: protocol for the study of in vivo effects of drugs. Clinical Chemistry. 1985;31(7):1141–1143. doi: 10.1093/clinchem/31.7.1141.
    1. Bengtsson C. Comparison between alprenolol and chlorthalidone as antihypertensive agents. Acta Medica Scandinavica. 1972;191:433–438.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi